Insider Transactions in Q1 2023 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,078
-2.62%
|
$11,858
$11.12 P/Share
|
|
Mar 20
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,671
+8.18%
|
-
|
|
Mar 20
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-6.07%
|
$6,974
$11.12 P/Share
|
|
Mar 20
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,158
+17.12%
|
-
|
|
Mar 20
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.74%
|
$9,636
$11.12 P/Share
|
|
Mar 20
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,982
+2.44%
|
-
|
|
Mar 20
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,523
-9.02%
|
$38,753
$11.12 P/Share
|
|
Mar 20
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,002
+23.51%
|
-
|
|
Mar 20
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
635
-5.86%
|
$6,985
$11.12 P/Share
|
|
Mar 20
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+16.64%
|
-
|
|
Mar 20
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-9.26%
|
$12,837
$11.12 P/Share
|
|
Mar 20
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,137
+14.5%
|
-
|
|
Mar 16
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.33%
|
$5,577
$11.46 P/Share
|
|
Mar 16
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+4.34%
|
-
|
|
Mar 16
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
256
-3.0%
|
$2,816
$11.46 P/Share
|
|
Mar 16
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+9.26%
|
-
|
|
Mar 16
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.49%
|
$6,347
$11.46 P/Share
|
|
Mar 16
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.66%
|
-
|
|
Mar 16
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,929
-6.66%
|
$21,219
$11.46 P/Share
|
|
Mar 16
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+18.49%
|
-
|
|
Mar 16
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
221
-2.49%
|
$2,431
$11.46 P/Share
|
|
Mar 16
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+8.01%
|
-
|
|
Mar 16
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
543
-4.94%
|
$5,973
$11.46 P/Share
|
|
Mar 16
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+8.29%
|
-
|
|
Jan 15
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
704
+7.98%
|
$6,336
$9.56 P/Share
|
|
Jan 15
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,844
+15.56%
|
$16,596
$9.56 P/Share
|